Short answer
Choose a supplier that can prove identity, safety and traceability for every batch, works within Malaysia’s regulatory framework for cell and gene therapy products, and gives your physicians direct access to its scientific and medical team. Price matters, but documentation matters more.
Key takeaways
- Cell and gene therapy products in Malaysia fall under NPRA’s CGTP framework; ask every supplier where its product and facility stand.
- Every batch should come with a test report covering identity, sterility, mycoplasma, endotoxin and viability.
- ISCT criteria are the common language for MSC identity: plastic adherence, specific surface markers and trilineage differentiation.
- A named medical director and a clear channel for reporting problems are as important as the cells themselves.
Why the choice of supplier matters
MSC products are living and variable. Two batches from different donors, passages or culture conditions can behave differently, which is why documentation and process control matter so much.
In Malaysia, cell and gene therapy products (CGTPs) are regulated as biologics by the National Pharmaceutical Regulatory Agency (NPRA), which published a second edition of its CGTP registration guidance in 2025[1]. Enforcement for CGTPs began in stages from 2021, with higher-risk (Class II) products requiring registration[2][3].
The 7-point checklist
Regulatory standing
Ask how the product and manufacturing facility fit NPRA’s CGTP framework, which class applies, and which licences or approvals are in place[1].
Source and donor screening
Which tissue are the cells from (umbilical cord, bone marrow, adipose)? How is donor consent obtained, and which infectious diseases are screened?
Identity to ISCT criteria
MSCs should adhere to plastic; express CD73, CD90 and CD105 (≥95%); lack CD34, CD45 and HLA-DR (≤2%); and differentiate into bone, fat and cartilage cells in vitro[4].
Safety release tests
Sterility, mycoplasma and endotoxin should be tested for every batch, with results on a batch certificate.
Viability and passage
Ask for viability at release and the maximum passage number used. Fewer passages and clear limits usually mean better control.
Cold chain and timing
Fresh or frozen? What temperature during transport, what delivery window, and are records handed over? See our guide on fresh vs cryopreserved MSCs.
Medical and scientific support
Is there a named medical director and scientist you can call? How are adverse events reported, and is training provided for your team?
Red flags
- No batch-level documentation, or reports that never change.
- Promises to cure specific diseases.
- Unclear cell source or donor screening.
- A pitch built only on price or volume discounts.
- Reluctance to discuss regulatory status.
A simple scoring sheet
| Criterion | What good looks like | Ask for |
|---|---|---|
| Regulation | Clear answer on CGTP class and approvals | Registration or licence details |
| Source | Named tissue source, documented consent and screening | Donor screening summary |
| Identity | ISCT markers reported per batch | Flow cytometry results |
| Safety | Sterility, mycoplasma, endotoxin per batch | Batch certificate |
| Viability | Stated minimum at release | Viability data and passage limit |
| Cold chain | Recorded temperature and timing | Sample delivery record |
| Support | Named medical and scientific contacts | Escalation and training plan |
Frequently asked questions
Do MSC products need NPRA registration in Malaysia?
Cell and gene therapy products fall under NPRA’s CGTP framework. Higher-risk (Class II) products require registration with the Drug Control Authority, while requirements for lower-risk products differ. Check the current guidance and ask your supplier for its regulatory status.
What is a batch certificate or certificate of analysis?
A batch-level document listing each test, its release criterion and the result for that specific batch, such as viability, surface markers, sterility, mycoplasma and endotoxin.
Which markers define a mesenchymal stem cell?
Under the ISCT minimal criteria, MSCs express CD73, CD90 and CD105, lack CD34, CD45 and HLA-DR, adhere to plastic and can differentiate into bone, fat and cartilage cells.
References
- National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Biologics: Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia, 2nd edition (2025). https://www.npra.gov.my/index.php/en/biologics-main-page.html
- Regulatory Oversight of Cell and Gene Therapy Products in Malaysia. Springer book chapter, 2023. https://link.springer.com/chapter/10.1007/978-3-031-34567-8_10
- Cell and gene therapy products in Malaysia: a snapshot of the industry’s current regulation preparedness. Cytotherapy. 2021. https://pubmed.ncbi.nlm.nih.gov/34362651/
- Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. https://doi.org/10.1080/14653240600855905
Links accessed 2 October 2026.
Responsible for the cell culture process and quality records at every passage.
Reviews clinical usage standards and works directly with physicians at partner hospitals and clinics.
This article is for general information and education and is not medical advice. Decisions about any cell therapy should be made with a registered physician. Meet the team